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Abstract 
SIRT1, an NAD-dependent histone/protein deacetylase, has classically been thought of as a 
nuclear protein. In this study, we demonstrate that SIRT1 is mainly localized in the nucleus of 
normal cells, but is predominantly localized in the cytoplasm of the cancer / transformed cells 
we tested. We found this predominant cytoplasmic localization of SIRT1 is regulated by 
elevated mitotic activity and PI3K/IGF-1R signaling in cancer cells. We show that aberrant 
cytoplasmic localization of SIRT1 is due to increased protein stability and is regulated by 
PI3K/IGF-1R signaling. In addition, we determined that SIRT1 is required for PI3K-mediated 
cancer cell growth. Our study represents the first identification that aberrant cytoplasm lo-
calization is one of the specific alternations to SIRT1 that occur in cancer cells, and 
PI3K/IGF-1R signaling plays an important role in the regulation of cytoplasmic SIRT1 stability. 
Our findings suggest that the over-expressed cytoplasmic SIRT1 in cancer cells may greatly 
contribute to its cancer-specific function by working downstream of the PI3K/IGF-1R signaling 
pathway. 
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INTRODUCTION 
Silent information regulator 1 (SIRT1) is a nico-
tinamide adenine dinucleotide (NAD)-dependent 
histone deacetylase (class III HDAC), which has been 
reported to be a crucial regulator in the pathophysi-
ology of aging, metabolic disease and neurodegener-
ative disorders [1-6]. In addition, SIRT1 has been 
shown to be a cancer cell-specific growth factor [7-10]. 
The knockdown of SIRT1 expression halts the growth 
of various tumor cell lines, but does not impact nor-
mal human epithelial cell growth [7-9].  
SIRT1 has classically been thought of as a nuc-
lear protein that functions to regulate histones and 
non-histone substrates with its deacetylase activity 
[4-6, 11-16]. Many factors in the nucleus have been 
identified as SIRT1 substrates, such as p53 [17], FOXO 
[18, 19], E2F [20], HIC1 [21], Rb [22], AR [23] and 
WRN [24, 25]. These SIRT1 nuclear substrates are in-
volved in various biological processes including 
stress-induced apoptosis, cell senescence, cell growth 
and DNA repair. Recent evidence suggests, however, 
that SIRT1 can also localize to the cytoplasm such as 
in murine pancreatic beta cells and rat cardiomyo-
cytes [26-29]. In cancer cells, SIRT1 cytoplasmic loca-
lization remains largely unidentified, and it is unclear 
if SIRT1 localization changes during carcinogenesis.  
In this study, we report for the first time that 
while SIRT1 is mainly localized in the nucleus of 
normal / primary cells, it is predominantly localized 
in the cytoplasm of cancer / transformed cells. Not 
only have we observed this localization pattern in 
prostate cancer cell lines, but we have also seen this in 
lung and breast cancer cells, transformed cell lines 
and prostate carcinoma tissues. We found that inhibi-
tion of PI3K/IGF-1R signaling or reduction of mitotic 
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activity in cancer cells reduces the abundance and 
protein stability of cytoplasmic SIRT1. Moreover, we 
show that SIRT1 is required for PI3K induced growth 
in prostate cancer cells. These results indicate that 
aberrant cytoplasmic localization of SIRT1 is a cancer 
specific alteration; PI3K/IGF-1R signaling increases 
the stability of cytoplasmic SIRT1 and ultimately re-
sults in its aberrant cytoplasmic localization. Because 
SIRT1 is an important protein deacetylase with both 
histone and non-histone substrates, changes in its 
localization will greatly affect its targets and will 
likely translate further into important functional con-
sequences for cell growth, survival and proliferation. 
Our findings suggest that the over-expressed cytop-
lasmic SIRT1 in cancer cells may greatly contribute to 
its cancer-specific function by working downstream 
of the PI3K/IGF-1R signaling pathway. 
MATERIALS AND METHODS  
Antibodies, plasmids and cell lines 
SIRT1 antibody (sc-74504, sc-19857) and Lamin 
A/C (sc-20681) were purchased from Santa Cruz 
Biotechnology (Santa Cruz, California). α-Tubulin 
(T6074) and β-Actin (A-1978) were purchased from 
Sigma Aldrich (St. Louis, Missouri). Anti-BrdU 
(NMM1645458) and anti-SIRT1 (07-131, 05-707) were 
purchased from Upstate-Millipore (Billerica, MA). 
SIRT1 antibody (C05187) was purchased from Epi-
tomics (Burlingame, CA). And anti-hSir2 antibody 
(856) [17] is a gift from Dr. Roy A. Frye (Pittsburgh 
Veterans Administration Medical Center, Pittsburgh, 
PA 15240). The SIRT1 RNAi vector (pSU-
PER.retro.puro-SIRT1) was generously provided by 
Dr. F. Picard (Laval University, Quebec, Canada). 
DU145, PC3, MCF-7, H460 were maintained in 
1x DMEM with 10% FBS. LNCaP, MRC5, BR3 and 
BR3neo cells were maintained in 1640 RPMI with 10% 
FBS. PZ-HPV-7 cells were maintained in Keratinocyte 
Serum-Free Medium (Invitrogen, catalog no. 10724) + 
Supplements (Invitrogen, catalog no. 37000-015). All 
cell lines were obtained from ATCC except the BR3 
cell line, which was a gift from Penny A. Jeggo (Uni-
versity of Sussex, East Sussex, BN1 9RQ, UK). Prostate 
cancer tissues and normal prostate tissues were pur-
chased from Cybrdi, Inc (Rockville, Maryland) 
Isolation of nuclear and cytoplasmic protein  
Nuclear and cytoplasmic proteins were isolated 
using NE-PER Nuclear and Cytoplasmic Extraction 
Reagents kit and following the detailed instructions 
provided (Pierce Biotechnology). Protease inhibitor 
tablets (Roche Diagnostics) and the phosphatase in-
hibitors, 10mM sodium pyrophosphate (Fisher Scien-
tific) and 100 μM sodium orthovanadate (Fisher 
Scientific), were added to the CERI and NER extrac-
tion reagents prior to use.  
Immunoblot 
Cells were lysed with 1% Nonidet P-40 lysis 
buffer (1% NP40, 150mm NaCl, 50mM Tris-HCl) with 
protease inhibitor (Roche Diagnostics). The concen-
tration of cell extract was measured by Bradford as-
say. The protein samples were subsequently sepa-
rated on an 8% SDS gel and analyzed with antibodies 
anti-SIRT1, Lamin A/C, β-Actin and α-Tubulin.  
Immunofluorescence Assay 
Cells (103-104) were plated in a Chamber Slide 
and incubated for 24 hours. Cells were fixed with 4% 
paraformaldehyde, treated with 0.1% Sodium Citrate 
+ 0.1%Triton 100 and with Image-iT FX Signal En-
hancer (Invitrogen). The cells were blocked with 3% 
BSA, treated with anti-SIRT1 antibodies, then incu-
bated with Alexa Fluor secondary antibodies (Invi-
trogen) and stained with DAPI. 
BrdU immunostainning was performed with 
mouse anti-BrdU antibody. After being labeled with 
20uM BrdU for 12 hours, standard indirect immu-
nofluorescence was performed as described above, 
except for one hour DNase I treatment before the 
blocking step. Images were collected using a decon-
volution microscope (Nikon deconvolution wide-field 
Epifluorescence system). 
Establishment of stable SIRT1-knockdown cell 
lines  
The pSUPER.retro.puro-SIRT1 or the pSU-
PER.retro vectors was used [30]. The Phoenix pack-
aging cell line was transfected with the pSU-
PER.retro.puro-SIRT1 or the pSUPER.retro vectors 
separately, using Lipofectamine 2000 (Invitrogen, 
Carlsbad, CA). After 48 hr, the medium containing 
retrovirus was collected, filtered, treated with poly-
brene, and transferred to DU145, PC3, LNCaP, H460 
and PZ-HPV-7 cell cultures. Infected cells were se-
lected with puromycin for isolation of stably infected 
colonies.  
Cell viability assay 
Cells were plated at a density of 5x103 cells per 
well on 96-well plates and cultured for 24hr, followed 
by treatment with Ly294002 (440202, CALBIOCHEM ) 
for 72hr. Then 20 µl MTS (G3580, Promega) was 
added to the medium for 1 h, and the absorbance was 
read at 490 nm in an Elisa plate reader. 
BrdU based cell proliferation assay  
2x104cells/well was seeded in a 96 well plate and 
BrdU (5mM) was added to each well for 24hr. The 
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cells were fixed and stained with anti-BrdU antibody 
for 20hr at RT. Anti-mouse IgG HRP was added for 30 
min and 100ul/well TMB peroxidase substrate was 
added for 30min. The integration of BrdU into the cell 
was determined at 450mM in the spectrophotometer 
microplate reader. The wells that did not receive cells 
and wells that contain cells but did not receive any 
BrdU reagent were included as controls. The detailed 
procedure can be found in the BrdU Cell Proliferation 
Assay (Cat# 2750) from Milipore (Billerica, MA) 
Real-Time RT-PCR 
 Total cellular RNA was isolated using Trizol 
reagent (Invitrogen Life Technologies, Carlsbad, CA) 
according to the manufacturer’s instructions. A 
two-step RT-PCR method was employed to synthes-
ize single-stranded cDNA (SuperScript TM III First 
Strand kit, Invitrogen, 18080-051). Target genes were 
analyzed by real-time PCR using Applied Biosystems 
7500 Fast Real-Time PCR System with SYBR Green I 
dye (Applied Biosystems, 4309155). The primers used 
were: SIRT1 forward: TAGTGACTGGACTCCA 
AGGCC, SIRT1 reverse: CAGTGTCATATCATCCA 
ACTCAGGT; β-actin forward: GAGAAAATCTGG 
CACCACACC; β-actin reverse: ATACCCCTCGTA 
GATGGGCAC. PCR reactions were performed in 
triplicate.  
RESULTS 
SIRT1 is predominantly localized in the cytop-
lasm in cancer / transformed cells 
In order to clearly understand the localization 
pattern of SIRT1 in cancer cells, we performed im-
munoblots combined with cell fractionation to ana-
lyze the localization of SIRT1. Lung, breast and pros-
tate cell lines, as well as tissues, were analyzed. The 
whole cell or tissue lysates were separated into nuc-
lear and cytoplasmic fractions, and immunoblots 
were performed with anti-SIRT1 antibodies. Unex-
pectedly, we found that SIRT1 (MW=120kd) was 
predominantly localized in the cytoplasm, rather than 
in the nucleus of cancer cells lines including DU145, 
PC3, LNCaP and LNCaP-C4-2B prostate cancer cell 
lines, H460 lung cancer cells, MCF-7 breast cancer cell 
lines, and prostate cancer tissues (Figure 1A and data 
not shown). Fractionation efficiency was confirmed 
by immunoblot with the α-tubulin antibody that re-
cognizes the protein in the cytoplasm, and the lamin 
A/C that binds the protein in the nucleus (Figure 1A). 
To ensure that this cytoplasmic localization of SIRT1 
was not occurring as a result of antibody epitope spe-
cificity, we subsequently performed immunoblots 
with several other SIRT1 antibodies and similar loca-
lization patterns of SIRT1 were observed (Figure S1). 
In order to further confirm the specificity of localized 
cytoplasmic SIRT1, we sought to determine if cytop-
lasmic SIRT1 could be specifically knocked down via 
RNA interference. Our results demonstrated that both 
nuclear and cytoplasmic SIRT1 (MW=120kd) levels 
are greatly reduced by RNA interference of SIRT1 
(siSIRT1) as compared to vector-transfected cells (si-
Vector) in DU145, PC3, LNCaP and H460 cell lines 
(Figure 1B and data not shown). 
We subsequently analyzed the localization pat-
terns of SIRT1 in normal cell lines and tissues. In con-
trast to cancer cell lines and tissues, we found SIRT1 
predominantly localized in the nucleus of normal 
cells, including the prostate cell line, PZ-HPV-7, nor-
mal prostate tissues, the normal lung cell line, MRC5 
(Figure 1C), and the normal human fibroblast cell line, 
BR3 (Figure 1D). These results indicate that the SIRT1 
localization pattern differs between cancer and nor-
mal cells. SIRT1 is predominantly localized in the cy-
toplasm of cancer cells and in the nucleus of normal 
cells.  
In addition, we compared the localization pat-
terns of SIRT1 in transformed and primary cells. We 
established a transformed and immortalized fibrob-
last cell line, BR3neo, through transfection of SV40 
Large T to a normal primary fibroblast cell line, 1BR3 
[31]. As shown in Fig.1D, SIRT1 is predominantly 
localized in the nucleus in BR3, the primary cell line, 
whereas it is predominantly localized in the cytop-
lasm in the BR3neo transformed cells. These results 
indicate that the predominant cytoplasmic localiza-
tion of SIRT1 is also associated with cell transforma-
tion.  
The over-expression of SIRT1 in cancer cells is 
mainly attributed to the elevation of cytoplasmic 
SIRT1 
After finding SIRT1 predominantly localized to 
the cytoplasm of cancer cells, we subsequently asked 
whether the previously documented overexpression 
of SIRT1 in cancer cells and tissues [32-36] is mainly 
attributed to increased cytoplasmic SIRT1. The levels 
of cytoplasmic and nuclear SIRT1 in cancer and nor-
mal cells were compared. The results demonstrated 
that the cytoplasmic SIRT1 level is robustly elevated 
in cancer cells compared to normal cells, whereas the 
nuclear SIRT1 is only marginally increased in cancer 
cells, such as prostate cancer cell line DU145 versus 
normal prostate cell PZ-HPV-7 and the transformed 
cell line BR3neo versus its parental normal cell BR3 
(Figure 1D). Thus, the over-expression of SIRT1 in 
cancer cells is mainly attributed to the elevation of 
cytoplasmic SIRT1.  
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Fig.1. Localization patterns of SIRT1 in cancer and normal cells. A. Cytoplasmic and nuclear fractions of DU145 
and PC3 cells and prostate cancer tissues were isolated, the concentration of nuclear and cytoplasmic protein was measured 
by Bradford assay, the same amount of nuclear and cytoplasmic protein was subjected to SDS gel, and immunoblots were 
performed with anti-SIRT1, α-tubulin and LaminA/C antibodies. B. Cytoplasmic and nuclear proteins were isolated from 
DU145 cells transfected with RNA interference of SIRT1 (siSIRT1) or vector control (siVector). Equal amounts of nuclear 
and cytoplasmic protein were loaded, and immunoblots were performed with the same antibodies used in Fig.1A. C. The 
nuclear and cytoplasmic fractions of normal prostate cell PZ-HPV-7, normal lung cell MRC5 and normal prostate tissues 
were prepared. The same amount of nuclear and cytoplasmic protein was loaded, and immunoblots were performed with 
the same antibodies as Fig.1A. D. The nuclear and cytoplasmic fractions of primary and transformed human fibroblast cells 
BR3 and BR3neo, normal prostate cell PZ-HPV-7 and prostate cancer cell line DU145 were prepared. Equal amounts of 
nuclear and cytoplasmic protein were loaded and immunoblots were performed with the same antibodies as Fig.1A.  
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Increased mitotic activity of cancer cells pro-
motes cytoplasmic localization of SIRT1  
Because cancer cells present a higher level of 
mitotic activity compared to normal cells, the finding 
that cytoplasmic SIRT1 is robustly increased in cancer 
cells seems to suggest a correlation between the SIRT1 
localization and the mitotic activity of cancer cells. 
Indeed, the doubling time of all of our analyzed can-
cer cells with predominant cytoplasmic localization of 
SIRT1 including DU145, PC3, H460 and BR3neo cells 
is less than 8 hours, which contrasts with the doubling 
time of 4 to 8 days for all the normal cells with pre-
dominant nuclear localization of SIRT1 including 
PZ-HPV-7, MRC5 and BR3 cells (data not shown). In 
order to understand whether the increased mitotic 
activity of cancer cells regulates the predominant cy-
toplasmic localization of SIRT1, we treated the cells 
with and without serum or hydroxyurea, which 
blocks the cell cycle, to study if reducing / blocking 
cancer cell proliferation / division would affect SIRT1 
localization. Immunofluorescence assays showed that 
SIRT1 is localized in both the nucleus and cytoplasm 
under normal culture conditions (10% FBS) (Figure 
2A). However, after serum depletion, we observed 
SIRT1 was largely diminished from the cytoplasm 
(Figure 2B). When the serum was replaced in the 
starved cells for 24hr, the depleted cytoplasmic SIRT1 
exhibited restoration (Figure 2C). Hydroxyurea 
treatment, specifically the S phase and cell division, 
had an effect similar to that of the serum depletion 
treatment (Figure 2D). These results suggest that in-
creased mitotic activity or growth signaling promotes 
the cytoplasmic localization of SIRT1, and conversely, 
the reduced mitotic activity or reduced growth sig-
naling decreased cytoplasmic SIRT1.  
Protein abundance rather than the translocation 
plays a dominant role in SIRT1 cytoplasm loca-
lization 
Since murine SIRT1, which has 84% homology 
with human SIRT1, has been reported to be a nuc-
leo-cytoplasmic shuttling protein mediated by a NLS 
and NES-dependent mechanism [37], we asked 
whether the decreased cytoplasmic SIRT1 induced by 
serum depletion and hydroxyurea treatment in cancer 
cells had translocated to the nucleus. Immunoblot 
analysis was performed with the fractionated nuclear 
and cytoplasmic proteins, which were treated with 
serum depletion or hydroxyurea. The results showed 
no increase in nuclear SIRT1 when cytoplasmic SIRT1 
is diminished by starvation (Figure 3A) or hydroxyu-
rea treatment (data not shown). In addition, we 
treated the cells with leptomycin B (LMB), an inhibitor 
of the NES-dependent nuclear exporter, and found 
SIRT1 in cancer cells neither accumulated in the nuc-
leus nor diminished from the cytoplasm in the pres-
ence of LMB (Figure 3B). Additionally, we treated the 
starved cells with serum with or without LMB and 
found that LMB treatment did not affect the cytop-
lasmic SIRT1 restoration by serum replacement (Fig-
ure 3C). These results suggest that predominant cy-
toplasmic localization induced by mitotic activity or 
growth signals is not due to SIRT1 translocation, but 
rather to the change in the abundance of cytoplasmic 
SIRT1.  
PI3K/IGF-1R signaling regulates protein stability 
of cytoplasmic SIRT1 
In order to identify which signaling pathway 
may regulate the abundance of cytoplasmic SIRT1, we 
treated the cells with various kinase inhibitors in-
cluding inhibitors Ly294002 and AG1024 for PI3K and 
IGF-1R respectively, as well as Rottlerin, a PKC inhi-
bitor and determined their effect on the abundance of 
cytoplasmic SIRT1. We found that treatment with 
Ly294002 and AG1024 reduced levels of cytoplasmic 
SIRT1, as determined by immunoblot (Figure 4A). The 
quantitative RT-PCR analysis shows no obvious 
change in SIRT1 mRNA levels in response to PI3K 
and IGF-1R inhibition (Figure 4B). We subsequently 
wanted to determine whether the reduced abundance 
of cytoplasmic SIRT1 was due to a protein stability 
change. The cytoplasmic and nuclear SIRT1 were iso-
lated from the cancer cells, and either treated with 
Ly294002 or AG1024 or left untreated and then com-
bined with cycloheximide (CHX) to inhibit protein 
synthesis, The SIRT1 protein level was then deter-
mined by immunoblotting. The results showed that 
inhibition of either IGF-1R or PI3K kinase activity 
reduced cytoplasmic SIRT1 stability (Figure 4C) but 
had no effect on the stability of nuclear SIRT1 (data 
not shown), as the half-life of cytoplasmic SIRT1 
changed from 11hr to 6hr for IGF-1R inhibition, and 
11hr to 4hr for PI3K inhibition (Figure 4C). These re-
sults suggest that PI3K/IGF-1R signaling regulates 
the protein stability of cytoplasmic SIRT1. 
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Fig.2. Mitotic signaling regulates cytoplasmic localization of SIRT1. DU145 cells were cultured in the chamber 
slide with DMEM+10% FBS. The immunofluorescence was performed with anti-SIRT1 antibody (sc 74504, Santa Cruz 
1:1000, RT 1hr) and Alexa Fluor 488 anti-mouse (Invitrogen, 1:200, RT 1hr). Nuclear protein was stained with DAPI 
(1:10,000). A. DU145 cells were cultured with DMEM+10% FBS. B. The DU145 cells that were cultured in the DMEM+10% 
FBS were shifted to serum-free DMEM for 48 hr. C. After culturing the DU145 cells in serum-free medium for 48hr, the 
medium was replaced with DMEM+10% FBS for 24hr. D. DU145 cells that were cultured in DMEM+10%FBS were treated 
with hydroxyurea for 24 hr.  
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Fig.3. Translocation does not play a dominant role in SIRT1 cytoplasm localization. A. The DU145 cells that 
were cultured in the DMEM+10% FBS were shifted to serum-free DMEM for 24 hr. The nuclear and cytoplasmic proteins 
were fractionated and equal amounts of nuclear and cytoplasmic protein were loaded, and immunoblots were performed 
with anti-SIRT1, Lamin A/C and tubulin antibodies. B. The DU145 cells were treated with either vehicle or 10nM LMB for 
two hours. The nuclear and cytoplasmic proteins were fractionated and equal amounts of nuclear and cytoplasmic protein 
were loaded and immunoblots were performed with anti-SIRT1, Lamin A/C and tubulin antibodies. C. The DU145 cells that 
were cultured in the serum-free DMEM were shifted to DMEM+10% FBS with or without LMB for 2hr. The nuclear and 
cytoplasmic proteins were fractionated and the same amounts of nuclear and cytoplasmic protein were loaded and im-
munoblots were performed with anti-SIRT1, Lamin A/C and tubulin antibodies. 
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Fig.4. PI3K and IGF-1R regulates the protein stability of cytoplasmic SIRT1. A. DU145 cells were treated with 
or without AG1024 (4µM) (left panel) or Ly294002 (20µM) (right panel) for 12hr. The nuclear and cytoplasmic proteins 
were prepared and equal amounts of nuclear and cytoplasmic protein were loaded to SDS gel. The immunoblot was per-
formed with anti-SIRT1, tubulin and LaminA/C antibodies. B. Transcript levels of SIRT1 was measured by quantitative 
RT-PCR analysis of RNA extracted from the cells treated with or without AG1024 (4µM) or Ly294002 (20µM) for 12hr. 
Transcript levels are expressed relative to β-actin transcripts. C. DU145 cells were pretreated with or without AG1024 
(4µM) (left panel) or Ly294002 (20µM) (right panel) for 30minutes, then treated with cycloheximide (10μg/ml). The 
nuclear and cytoplasmic proteins were isolated after treatment with cycloheximide for 0, 5 and 15hr and the same amounts 
of nuclear and cytoplasmic proteins were subjected to SDS gel. The immunoblot was performed with anti-SIRT1 and an-
ti-tubulin antibodies.  
 
 
 
SIRT1 functions downstream of PI3K and regu-
lates prostate cancer cell growth 
PI3K and IGF-1R have been reported to play an 
important role in prostate cancer cell growth and 
survival [38, 39]. We found that PI3K can regulate 
cytoplasmic SIRT1 stability, suggesting that SIRT1 
may play a role in PI3K-mediated cancer cell growth. 
We therefore firstly performed an MTS assay to study 
the effect of SIRT1 knockdown on PI3K inhibitor in-
duced cell growth arrest. The results showed that 
Ly294002 treatment induced great inhibition in 
SIRT1-overexpressed prostate cancer cells, induced 
50% growth inhibition in PC3 cells and 45% in LNCaP 
cells with wt SIRT1, while inducing only a 20% inhi-
bition in SIRT1 knockdown cells (Figure 5A & 5B). 
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Fig.5. SIRT1 silencing attenuates PI3K inhibition-mediated prostate cancer cell growth arrest. Prostate 
cancer cell lines PC3 (5A) and LNCaP (5B) in which SIRT1 had been knocked down by siRNA expression (siSIRT1) or 
empty-vector-transfected cells (siVector) were exposed to the Ly292002 (20µM).Viable cells were quantitated at 72hr by 
MTS assay. The error bars represent the SEM. The SIRT1 knockdown efficiency was shown in 5A and 5B lower panel. C. 
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The SIRT1 knockdown (siSIRT1) and empty-vector control (siVector) PC3 cells were treated with or without Ly292002 
(20µM) for 24hr, then exposed to the BrdU (20uM) for another 24hr. The immunostaining was performed with anti-BrdU 
antibody (NMM1645458) and anti-mouse 594 secondary antibody. The images were taken with Nikon deconvolution 
wide-field Epifluorescence system. 100x. D. The SIRT1 knockdown (siSIRT1) and empty-vector control (siVector) PC3 cells 
were treated with or without Ly292002 (20µM) for 24hr, then exposed to the BrdU (4uM) for 24hr. The cells were fixed, 
immunostainned with anti-BrdU antibody and peroxidase conjugate secondary antibody; the peroxidase substrate was 
added and plates were read at 450nM. The error bars represent the SEM. E. MTS analysis for normal prostate cells 
PZ-HPV-7 cells. The experiment conditions are the same as 5A and 5B. The SIRT1 knockdown efficiency was shown in 5E 
lower panel. 
 
Similar results were seen using Brdu immunos-
taining (Figure 5C) and BrdU-based proliferation as-
say (Figure 5D). The results show that PI3K inhibition 
result in much more reduction of Brdu integration to 
the cells in SIRT1 wild type cells than in SIRT1 
knockdown cells (Figure 5C & 5D). However, in 
normal prostate PZ-HPV-7 cells in which SIRT1 ex-
pression is lower and is predominantly in the nucleus, 
PI3K inhibition induce little growth arrest for both 
SIRT1 wt and SIRT1 knockdown cells (Figure 5E). 
These results suggest that SIRT1 is an important 
downstream target of PI3K in the regulation of cancer 
cell growth and survival, and overexpressed cytop-
lasmic SIRT1 in cancer cells may play an important 
role in this regulation. 
DISCUSSION 
In this study we demonstrated that SIRT1 is 
predominantly localized in the cytoplasm of cancer 
cells, while in normal cells, SIRT1 is predominantly 
localized in the nucleus. SIRT1 cytoplasmic localiza-
tion in cancer cells is largely unidentified and it is 
unclear if SIRT1 localization has any changes during 
carcinogenesis. Our study represents the first identi-
fication that aberrant cytoplasmic localization is one 
of the cancer-specific alternations to SIRT1. This 
finding may suggest a new mechanism for SIRT1 
function as a cancer-specific survival factor by tar-
geting cytoplasmic proteins.  
In contrast to its well-described role in the nuc-
leus, the function of cytoplasmic SIRT1 is largely un-
known. However, recent findings that some cytoplas-
mic proteins can be deacetylated by SIRT1 provide 
important insights into the function of cytoplasmic 
SIRT1. SIRT1 was found to enhance IGF-1 signaling 
by deacetylating ISH-2, which is a cytoplasmic protein 
[27]. SIRT1 also deacetylates cytoplasmic cortactin 
and promotes cancer cell migration [40]. In addition, 
SIRT1 was found to promote the activation of cytop-
lasmic kinases, including AMPK, Ras-MAPK, Erk and 
S6K1 [8, 41, 42]. Furthermore, SIRT1 was shown to 
regulate nucleo-cytoplasmic shuttling of transcription 
factors, including FOXO3a, FOXO1, and PGC-1 
[43-47]. Because many known SIRT1 substrates, in-
cluding p53 and NF-κB, also shuttle between the 
nucleus and cytoplasm, SIRT1 could regulate their 
function via cytoplasmic deacetylase activity. Recent 
study show that cytoplasmic SIRT1 can promote 
nerve growth factor (NGF)-induced neurite out-
growth [48]. In addition, we found that SIRT1 can 
form a complex with E-cadherin in the cytoplasm and 
regulate cell-cell adhesion (unpublished data). These 
results provide support for the association of cytop-
lasmic SIRT1 with kinase signaling, nuc-
leo-cytoplasmic shuttling of the transcription factors, 
and with the proteins involved in cell adhesion and 
migration. SIRT1 may now prove to be more multifa-
ceted in function due to its newly discovered predo-
minant cytoplasmic localization, which may play a 
critical role in cancer cell development and progres-
sion by targeting cytoplasmic substrates. 
In this paper we also elucidated the regulation of 
SIRT1 predominant cytoplasmic localization in cancer 
cells. Ectopically expressed murine SIRT1 has been 
reported as a nucleocytoplasmic shuttle protein me-
diated by a NLS and NES-dependent mechanism [37]. 
However in human cancer cells, our results show that 
the nucleocytoplasmic shuttle does not seem to play a 
significant role in the regulation of increased cytop-
lasmic localization of SIRT1. Although we cannot ex-
clude that there may exist translocation for small 
amount of SIRT1 in the cancer cells, the nuc-
lear-cytoplasm shuttle is not a major mechanism in 
the regulation of cytoplasmic localization of SIRT1 in 
cancer cells, as there is no obvious change in the nuc-
lear SIRT1 level while cytoplasmic SIRT1 is altered. 
Instead, we found that PI3K/IGF-1R signaling regu-
lates cytoplasmic SIRT1 stability and abundance, 
which suggests the PI3K/IGF-1R-mediated cytop-
lasmic SIRT1 stability plays a dominant role in the 
regulation of aberrant cytoplasm localization. The 
elevated SIRT1 protein levels in cancer cells may re-
flect abnormal stabilization induced by overactive 
PI3K/IGF-1R signaling.  
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Fig.S1. SIRT1 localization determined by both Immunofluorescence and immunobolt analysis. DU145 cells 
were cultured in the chamber slide with DMEM+10% FBS for the immunoflurorescence analysis (left panel). A. Anti-SIRT1 
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(C05187, Epitomics, 1:100, RT 1hr) and Alexa Fluor 488 goat anti-rabbit (Invitrogen, 200x, RT 1hr). B. Anti-hSir2 (856, 
1:500, RT 1hr) and Alexa Fluor 488 goat anti-rabbit (Invitrogen, 200x, RT 1hr). C. Anti-SIRT1 (SC-19857, Santa Cruz, 1:50. 
RT 1hr) and Alexa Fluor 546 donkey anti-goat (Invitrogen, 100x, RT 1hr). D. Anti-SIRT1 (07-131, Milipore, 1:50, RT 1hr) 
and Alexa Fluor 488 goat anti-rabbit (Invitrogen, 200x, RT 1hr). E. Anti-SIRT1 (sc-74504, Santa Cruz, 1:1000, RT 1hr) and 
Alexa Fluor 488 goat anti-mouse (Invitrogen, 200x, RT 1hr). F. Anti-SIRT1 (05-707, upstate, 1:1000, RT 1hr) and Alexa Fluor 
594 goat anti-mouse (Invitrogen, 100x, RT 1hr). Cytoplasmic and nuclear fractions of DU145 cells were isolated and same 
amount of nuclear and cytoplasmic protein were subjected to SDS gels, and immunoblots were performed (right panel). 
A. Anti-SIRT1 (C05187, Epitomics, 1:500, RT 1hr). B. Anti-hSir2 (856, 1:1000, RT 1hr). C. Anti-SIRT1 (SC-19857, Santa 
Cruz, 1:200, 4oC O/N). D. Anti-SIRT1 (07-131, Milipore, 1:500, 4oC O/N). E. Anti-SIRT1 (sc-74504, Santa Cruz, 1:1000, RT 
1hr). F. Anti-SIRT1 (05-707, upstate, 1:1000, RT 1hr). 
 
 
Activated phosphoinositide 3-kinase (PI3K) is an 
important signaling molecule and acts as a key sur-
vival factor involved in the control of cell prolifera-
tion, apoptosis and oncogenesis [49]. Our results show 
that SIRT1 is required for PI3K mediated cancer cell 
growth. The tumor suppressor PTEN is an inhibitor of 
PI3K and its loss or mutation has been associated with 
many different types of cancer; in the absence of 
PTEN, PI3K is constitutively activated and strongly 
inhibits apoptosis and promotes cell survival and 
proliferation [39, 50]. Interestingly, SIRT1 has been 
shown to deactivate PTEN by deacetylation [51] and 
our results show that SIRT1 can be regulated by PI3K. 
It seems that there could be a positive feedback loop 
in the cell whereby SIRT1 is a downstream target of 
PI3K signaling, which may sequester SIRT1 in the 
cytoplasm to deacetylate PTEN and act on other 
non-histone substrates regulating cell growth and 
survival. Indeed we found SIRT1 is required for PI3K 
mediated cell growth in prostate cancer cells in which 
cytoplasmic SIRT1 is overexpressed, but inhibiting 
PI3K in the SIRT1 deficient cells, or normal prostate 
cells in which SIRT1 expression is lower and is pre-
dominantly in the nucleus, produces a much lower 
percentage of growth inhibition (Figure 5). These re-
sults suggest that overexpressed cytoplasmic SIRT1 in 
cancer cells may be an important downstream target 
of PI3K in the regulation of prostate cancer cell 
growth and survival. However, further investigation 
is needed to elucidate the detailed mechanism by 
which cytoplasmic SIRT1 is involved in 
P13K-mediated cell growth.  
Finally, in this study we have clarified the cause 
of the controversial report for SIRT1 localization in 
cancer cells [13, 26, 28, 34]. Due to the fact that pub-
lished data for SIRT1 localization is mainly generated 
from immunofluorescence analysis, we performed an 
immunofluorescence assay with the most available 
SIRT1 antibodies to study whether antibody specific-
ity played a role in the controversial results. When we 
stained the same cells with a different anti-SIRT1 an-
tibody, the immunofluorescence results show that 
while some antibodies only stain nuclear SIRT1 
(C05187 Epitomics) [36], others were either specific for 
cytoplasmic SIRT1 (05-707 upstate) [26] or recognized 
both nuclear and cytoplasmic SIRT1 forms ( 856 [17, 
52], sc-74504, and SC-19857 (Santa Cruz) and 
07-131(milipore) (Figure S1). This data suggests that 
antibody specific epitopes play a dominant role in 
determining if SIRT1 is localized in the nucleus or 
cytoplasm while using the immunofluorescence as-
say, and may explain the controversial reports about 
SIRT1 localization. In order to eliminate the antibody 
specificity issues produced in the immunofluores-
cence experiments, we performed an immunoblot 
combined with nuclear-cytoplasmic SIRT1 fractiona-
tion to determine SIRT1 localization. All tested anti-
bodies in the immunoblot assays have shown that 
SIRT1 is predominantly localized in the cytoplasm 
regardless of whether or not the antibody in the im-
munofluorescence assay recognized only nuclear 
SIRT1, only the cytoplasmic SIRT1, or both the nuclear 
and cytoplasmic SIRT1 (Figure S1). Thus, the immu-
noblot method can overcome the antibody specificity 
issues that arise in immunofluorescence assays. It is 
unclear why the SIRT1 antibody has such a dramatic 
effect in recognizing nuclear or cytoplasmic SIRT1 in 
immufluorescence. SIRT1 may form some structure or 
conformation with other proteins or organelles, the-
reby hiding the isotope and making recognition more 
difficult by some antibodies. It is also possible that 
some SIRT1 antibodies may have non-specific recog-
nition for the nuclear proteins. Therefore, extra cau-
tion should be used when interpreting the immunof-
lurescence or IHC results regarding SIRT1 localization 
or expression. The nuclear and cytoplasmic fractiona-
tion combined with immunoblot with SIRT1 antibody 
is a good way to study SIRT1 localization.  
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